Lightest-neutralino decays in R_p-violating models with dominant lambda^{prime} and lambda couplings

Decays of the lightest neutralino are studied in R_p-violating models with operators lambda^{prime} L Q D^c and lambda L L E^c involving third-generation matter fields and with dominant lambda^{prime} and lambda couplings. Generalizations to decays of the lightest neutralino induced by subdominant lambda^{prime} and lambda couplings are straightforward. Decays with the top-quark among the particles produced are considered, in addition to those with an almost massless final state. Phenomenological analyses for examples of both classes of decays are presented. No specific assumption on the composition of the lightest neutralino is made, and the formulae listed here can be easily generalized to study decays of heavier neutralinos. It has been recently pointed out that, for a sizable coupling lambda^{prime}_{333}, tau-sleptons may be copiously produced at the LHC as single supersymmetric particles, in association with top- and bottom-quark pairs. This analysis of neutralino decays is, therefore, a first step towards the reconstruction of the complete final state produced in this case.Comment: 40 pages, 11 figures, version to appear in JHE

One-loop Neutron Electric Dipole Moment from Supersymmetry without R-parity

We present a detailed analysis together with exact numerical calculations on one-loop contributions to neutron electric dipole moment from supersymmetry without R-parity, focusing on the gluino, chargino, and neutralino contributions. Apart from the neglected family mixing among quarks, complete formulae are given for the various contributions, through the quark dipole operators, to which the present study is restricted. We discuss the structure and main features of the R-parity violating contributions and the interplay between the R-parity conserving and violating parameters. In particular, the parameter combination $\mu_i^*\lambda^{\prime}_{i11}$, under the optimal parametrization adopted, is shown to be solely responsible for the R-parity violating contributions in the supersymmetric loop diagrams. While $\mu_i^*\lambda^{\prime}_{i11}$ could bear a complex phase, the latter is not necessary to have a R-parity violating contribution.Comment: 43 pages Revtex with 15 eps- and 4 ps- figure files incoporated; proofread version to be published in Phys. Rev.

Parton distributions in the virtual photon target up to NNLO in QCD

Parton distributions in the virtual photon target are investigated in perturbative QCD up to the next-to-next-to-leading order (NNLO). In the case $\Lambda^2 \ll P^2 \ll Q^2$, where $-Q^2$ ($-P^2$) is the mass squared of the probe (target) photon, parton distributions can be predicted completely up to the NNLO, but they are factorisation-scheme-dependent. We analyse parton distributions in two different factorisation schemes, namely $\bar{\rm MS}$ and ${\rm DIS}_{\gamma}$ schemes, and discuss their scheme dependence. We show that the factorisation-scheme dependence is characterised by the large-$x$ behaviours of quark distributions. Gluon distribution is predicted to be very small in absolute value except in the small-$x$ region.Comment: 28 pages, 5 figures, version to appear in Eur. Phys. J.

Fermion Electric Dipole Moments in Supersymmetric Models with R-parity Violation

We analyze the electron and neutron electric dipole moments induced by R-parity violating interactions in supersymmetric models. It is pointed out that dominant contributions can come from one-loop diagrams involving both the bilinear and trilinear R-parity odd couplings, leading to somewhat severe constraints on the products of those couplings.Comment: Revtex, 19pp, four figures in axodraw.st

CP asymmetries in the supersymmetric trilepton signal at the LHC

In the CP-violating Minimal Supersymmetric Standard Model, we study the production of a neutralino-chargino pair at the LHC. For their decays into three leptons, we analyze CP asymmetries which are sensitive to the CP phases of the neutralino and chargino sector. We present analytical formulas for the entire production and decay process, and identify the CP-violating contributions in the spin correlation terms. This allows us to define the optimal CP asymmetries. We present a detailed numerical analysis of the cross sections, branching ratios, and the CP observables. For light neutralinos, charginos, and squarks, the asymmetries can reach several 10%. We estimate the discovery potential for the LHC to observe CP violation in the trilepton channel.Comment: 39 pages, 8 figures, version to appear in EPJC, discussion(s) added, typo in (D.79), (D.118) corrected, new Fig. 7; The European Physical Journal C, Volume 72, Issue 3, 201

Probing exotic phenomena at the interface of nuclear and particle physics with the electric dipole moments of diamagnetic atoms: A unique window to hadronic and semi-leptonic CP violation

The current status of electric dipole moments of diamagnetic atoms which involves the synergy between atomic experiments and three different theoretical areas -- particle, nuclear and atomic is reviewed. Various models of particle physics that predict CP violation, which is necessary for the existence of such electric dipole moments, are presented. These include the standard model of particle physics and various extensions of it. Effective hadron level combined charge conjugation (C) and parity (P) symmetry violating interactions are derived taking into consideration different ways in which a nucleon interacts with other nucleons as well as with electrons. Nuclear structure calculations of the CP-odd nuclear Schiff moment are discussed using the shell model and other theoretical approaches. Results of the calculations of atomic electric dipole moments due to the interaction of the nuclear Schiff moment with the electrons and the P and time-reversal (T) symmetry violating tensor-pseudotensor electron-nucleus are elucidated using different relativistic many-body theories. The principles of the measurement of the electric dipole moments of diamagnetic atoms are outlined. Upper limits for the nuclear Schiff moment and tensor-pseudotensor coupling constant are obtained combining the results of atomic experiments and relativistic many-body theories. The coefficients for the different sources of CP violation have been estimated at the elementary particle level for all the diamagnetic atoms of current experimental interest and their implications for physics beyond the standard model is discussed. Possible improvements of the current results of the measurements as well as quantum chromodynamics, nuclear and atomic calculations are suggested.Comment: 46 pages, 19 tables and 16 figures. A review article accepted for EPJ

Search and study of Quark Gluon Plasma at the CERN-LHC

The major aim of nucleus-nucleus collisions at the LHC is to study the physics of strongly interacting matter and the quark gluon plasma (QGP), formed in extreme conditions of temperature and energy density. We give a brief overview of the experimental program and discuss the signatures and observables for a detailed study of QGP matter.Comment: 15 pages, Invited article for the volume on LHC physics to celebrate the Platinum Jubilee of the Indian National Science Academy, Edited by Amitava Datta, Biswarup Mukhopadhyaya and Amitava Raychaudhuri (Jan 2009

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Background: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg. Methods: In this 52-week, multicentre, randomised, open-label, phase 3a trial, we recruited patients with type 2 diabetes from 81 sites in ten countries. Patients were eligible if they were aged 18 years or older (19 years or older in South Korea), had type 2 diabetes (diagnosed ≥90 days before screening), HbA1c of 7·5–9·5% (58–80 mmol/mol), and were inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (for 90 days or more before screening). Participants were randomly assigned (1:1) by use of an interactive web-response system, stratified by background glucose-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 14 mg once daily or sitagliptin 100 mg once daily. To approximate treatment individualisation in clinical practice, oral semaglutide dose could be adjusted on the basis of prespecified HbA1c and tolerability criteria. Two efficacy-related estimands were prespecified: treatment policy (regardless of treatment discontinuation or use of rescue medication) and trial product (on treatment and without use of rescue medication) for participants randomly assigned to treatment. The primary endpoint was achievement of HbA1c of less than 7% (53 mmol/mol) at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02849080, and European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing. Findings: Between Sept 20, 2016, and Feb 7, 2017, of 804 patients assessed for eligibility, 504 were eligible and randomly assigned to oral semaglutide (n=253) or sitagliptin (n=251). Most participants were male (285 [57%] of 504) with a mean age of 57·4 years (SD 9·9). All participants were given at least one dose of their allocated study drug except for one participant in the sitagliptin group. From a mean baseline HbA1c of 8·3% (SD 0·6%; 67 mmol/mol [SD 6·4]), a greater proportion of participants achieved an HbA1c of less than 7% with oral semaglutide than did with sitagliptin (treatment policy estimand: 58% [134 of 230] vs 25% [60 of 238]; and trial product estimand: 63% [123 of 196] vs 28% [52 of 184]). The odds of achieving an HbA1c of less than 7% was significantly better with oral semaglutide than sitagliptin (treatment policy estimand: odds ratio [OR] 4·40, 95% CI 2·89–6·70, p<0·0001; and trial product estimand: 5·54, 3·54–8·68, p<0·0001). The odds of decreasing mean bodyweight from baseline to week 52 were higher with oral semaglutide than with sitagliptin (estimated mean change in bodyweight, treatment policy estimand: −2·6 kg [SE 0·3] vs −0·7 kg [SE 0·2], estimated treatment difference [ETD] −1·9 kg, 95% CI −2·6 to −1·2; p<0·0001; and trial product estimand: −2·9 kg [SE 0·3] vs −0·8 kg [SE 0·3], ETD −2·2 kg, −2·9 to −1·5; p<0·0001). Adverse events occurred in 197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagliptin group, and nausea was the most common adverse event with oral semaglutide (53 [21%]). Two deaths occurred in the sitagliptin group during the trial. Interpretation: Oral semaglutide, with flexible dose adjustment, based on efficacy and tolerability, provided superior glycaemic control and weight loss compared with sitagliptin, and with a safety profile consistent with subcutaneous GLP-1 receptor agonists. Funding: Novo Nordisk A/S

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

Background:Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.Methods and Findings:1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the hazard ratio (HR) was ≤1.35 when 30% of participants had treatment failure.An independent monitoring board recommended stopping study follow-up prior to accumulation of 472 treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72-1.27; p = 0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p<0.001) and there was a significant interaction between sex and regimen safety (HR 0.50, CI 0.39-0.64 for women; HR 0.79, CI 0.62-1.00 for men; p = 0.01). Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of 81 wk there were 108 failures (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12-2.04; p = 0.007).Conclusion: EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse multinational settings. Superior safety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of this regimen for initial treatment of HIV-1 infection in resource-limited countries. ATV+DDI+FTC had inferior efficacy and is not recommended as an initial antiretroviral regimen.Trial Registration:http://www.ClinicalTrials.gov NCT00084136

Ofloxacin ocular inserts: Design, Formulation and Evaluation

In developing a drug delivery strategy, issues of absorption, distribution, metabolism, and elimination must be considered. The eye presents unique opportunities and challenges when it comes to the delivery of pharmaceuticals. While absorption by this route is bungling, there are few side effects with conventional ocular dosage forms. Hence, ocular inserts were prepared with prolonged release of drug and minimum swelling within cul-de-sac using ofloxacinas a model drug; and hydroxy propyl methyl cellulose, methyl cellulose, poly vinyl pyrrolidone and poly vinyl alcohol as polymers. PEG-400 was incorporated as plasticizer. The main purpose of the study was to deliver the drug in zero order kinetics. Solvent casting technique was followed to prepare ofloxacin ocular films. Eight formulations were formulated and subjected to various physicochemical evaluations. Ocular inserts prepared were smooth and passed all the evaluation tests performed. Formulation OF2 shows a maximum cumulative percentage drug release of 91.27 % at the end of 24 hours. Ocuserts formulated also passed the test for sterility. They showed zero-order release of the drug in the in vitro and in vivo release studies. The drug in the films was found to be active against selected microorganisms as was proved by microbial efficacy studies. A high correlation coefficient was found between in vitro and in vivo release rate studies. Shelf-life of the product was found to be more than one year.The results of in vitro, in vivo, kinetic treatment (zero order and Korsemeyer s regression values) and rate constant k value suggest that OF2 was the best formulation among the formulations studied for formulating ofloxacin ocular insert